| 2.49 -0.05 (-1.97%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.79  |
1-year : | 4.38 |
| Resists | First : | 3.24 |
Second : | 3.75 |
| Pivot price | 2.88 |
|||
| Supports | First : | 2.44 | Second : | 2.03 |
| MAs | MA(5) : | 2.56 |
MA(20) : | 2.95 |
| MA(100) : | 2.95 |
MA(250) : | 2.58 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.5 |
D(3) : | 5.2 |
| RSI | RSI(14): 33.4 |
|||
| 52-week | High : | 6.01 | Low : | 1.12 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NRXP ] has closed above bottom band by 12.0%. Bollinger Bands are 54.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.58 - 2.59 | 2.59 - 2.6 |
| Low: | 2.44 - 2.45 | 2.45 - 2.47 |
| Close: | 2.47 - 2.49 | 2.49 - 2.51 |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Mon, 10 Nov 2025
HOPE Therapeutics (NASDAQ: NRXP) starts ONE-D with Ampa; 72% remission in 6 weeks - Stock Titan
Mon, 27 Oct 2025
NRx Pharmaceuticals (NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 11.5 (%) |
| Held by Institutions | 25.5 (%) |
| Shares Short | 916 (K) |
| Shares Short P.Month | 680 (K) |
| EPS | -2.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -174.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | -1.13 |
| PEG Ratio | 0 |
| Price to Book value | -1.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|